Tibolone
Tibolone is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target estrogen receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | 1 | 4 | 1 | 7 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | — | 3 | 1 | 4 |
| Depression | D003863 | — | F33.9 | 1 | — | — | 2 | 1 | 4 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | 2 | — | 3 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 1 | 1 | — | 2 |
| Postmenopause | D017698 | — | — | — | — | 1 | 1 | — | 2 |
| Amenorrhea | D000568 | — | N91.2 | — | — | — | 1 | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | — | 1 | — | 1 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | 1 | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | — | 3 |
| Climacteric | D002979 | — | — | — | — | 1 | — | 1 | 2 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 1 | 1 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | — | 1 | 1 |
| Leiomyoma | D007889 | HP_0000131 | D25 | — | — | — | — | 1 | 1 |
| Myofibroma | D047708 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tibolone |
| INN | tibolone |
| Description | Tibolone is estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormone receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis. It has a role as a hormone agonist and a bone density conservation agent. It is a 17beta-hydroxy steroid and a terminal acetylenic compound. |
| Classification | Small molecule |
| Drug class | anabolic steroids; steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C |
Identifiers
| PDB | — |
| CAS-ID | 5630-53-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103774 |
| ChEBI ID | 32223 |
| PubChem CID | 444008 |
| DrugBank | DB09070 |
| UNII ID | FF9X0205V2 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ESR1
ESR1
Organism
Homo sapiens
Gene name
ESR1
Gene synonyms
ESR, NR3A1
NCBI Gene ID
Protein name
estrogen receptor
Protein synonyms
E2 receptor alpha, ER-alpha, Estradiol receptor, estrogen nuclear receptor alpha, estrogen receptor alpha E1-E2-1-2, estrogen receptor alpha E1-N2-E2-1-2, Nuclear receptor subfamily 3 group A member 1, oestrogen receptor alpha
Uniprot ID
Mouse ortholog
Esr1 (13982)
estrogen receptor (Q9QY52)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,740 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
87 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use